Comparison · NCT00619112-ca8c8a01
Glioblastoma vs Grade III Glioma: Patients Progressing Within 6 Months After 6th Adjuvant Course of Temozolomide
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Glioblastoma vs Grade III Glioma: Patients Progressing Within 6 Months After 6th Adjuvant Course of Temozolomide. Trial comparisons, record NCT00619112-ca8c8a01. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00619112-ca8c8a01
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.1 | 0.0396 | 0.231 | wilson | |
| Risk in group 2 | 0.05 | 0.00888 | 0.236 | wilson | |
| Risk difference, group 1 minus group 2 | 0.05 | -0.146 | 0.187 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2 | 0.239 | 16.7 | log | |
| Odds ratio, group 1 over group 2 | 2.11 | 0.22 | 20.2 | log | |
| Number needed to treat, for one more participant with the outcome on Glioblastoma than on Grade III Glioma | 20 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Glioblastoma | Glioblastoma patients were treated with temozolomide at a dose of 150mg/m\^2 daily for seven consecutive days of every other week.~One 28-day cycle included treatment with temozolomide on days 1-7 and days 15-21 with no treatment on days 8-14 | 4 | 40 | OG000 |
| Group 2 | Grade III Glioma | Grade III glioma patients were treated with temozolomide at a dose of 150mg/m\^2 daily for seven consecutive days of every other week.~One 28-day cycle included treatment with temozolomide on days 1-7 and days 15-21 with no treatment on days 8-14 | 1 | 20 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Patients Progressing Within 6 Months After 6th Adjuvant Course of Temozolomide
- Description
- Time frame
- Within 6 months after 6th adjuvant course of temozolomide
- Population
Source ClinicalTrials.gov
Trial
- Title
- Temozolomide in Treating Patients With Recurrent High-Grade Glioma
- NCT number
- NCT00619112
- Phases
- PHASE2
- Conditions
- Recurrent Central Nervous System Neoplasm
- Interventions
- temozolomide
- Lead sponsor
- University of California, San Francisco
- Results first posted
- 2013-10-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00619112?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00619112-ca8c8a01